Tchekmedyian N S, Hickman M, Siau J, Greco F A, Keller J, Browder H, Aisner J
Pacific Coast Hematology/Oncology Medical Group, Long Beach, California.
Cancer. 1992 Mar 1;69(5):1268-74. doi: 10.1002/cncr.2820690532.
High-dose megestrol acetate has been associated with increased appetite and weight. To examine the effects of high-dose megestrol acetate in the treatment of anorexia and weight loss in patients with advanced hormone-insensitive malignant lesions, a randomized double-blind placebo-controlled trial was conducted. Patients receiving megestrol acetate for 1 month reported a significant improvement in appetite and adequacy of food intake compared with those receiving placebo. A three-item scale measuring appetite, adequacy of food intake, and concern about weight revealed a higher improvement with megestrol acetate than with placebo. Patients who worsened while receiving placebo had similar favorable changes after the cross over to megestrol acetate. These data indicate that megestrol acetate may improve appetite and food intake in patients with advanced cancer.
大剂量醋酸甲地孕酮与食欲增加和体重上升有关。为了研究大剂量醋酸甲地孕酮对晚期激素不敏感恶性病变患者厌食和体重减轻的治疗效果，开展了一项随机双盲安慰剂对照试验。与接受安慰剂的患者相比，接受醋酸甲地孕酮治疗1个月的患者在食欲和食物摄入量充足方面有显著改善。一项测量食欲、食物摄入量充足程度和对体重的关注程度的三项量表显示，醋酸甲地孕酮组的改善程度高于安慰剂组。在接受安慰剂治疗期间病情恶化的患者在改用醋酸甲地孕酮治疗后也有类似的良好变化。这些数据表明，醋酸甲地孕酮可能改善晚期癌症患者的食欲和食物摄入量。
